U.S. FDA: Seeks to remove suicide warning from GLP-1 drugs
The U.S. Food and Drug Administration (FDA) stated that it requires the removal of warnings regarding the exacerbation of "suicidal behavior" (SI/B) from a range of GLP-1 medications. The FDA found no evidence that the use of these drugs increases the risk of SI/B. The affected medications are Novo Nordisk's Wegovy, Saxenda, and Eli Lilly's Zepbound.
The FDA's review covered 91 placebo-controlled trials involving 107,910 patients; the results showed that the risk of suicidal thoughts or behaviors did not increase.
Previously, a survey in the UK also found no evidence of a link between weight loss drugs and suicide
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments